The aim is to evaluate the effect of Lubeluzole compared to placebo in the treat ment of acute ischemia stroke within 6 hrs. The primary hypothesis is that Lubeluzole will reduce mortality without increasing morbidity, therefore the primary endpoint is mortality at 12 months and the secondary endpoints are functional and neurological recovery.
Showing the most recent 10 out of 1103 publications